Associations of haemostatic variables with body mass index: A community-based study

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 6, 2003, Pages 569-573

  Bowles, Louise K ^a   Cooper, Jackie A ^a   Howarth, David J ^a   Miller, George J ^a   MacCallum, Peter K ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Body mass index; Fibrinolysis; Haemostasis; Inflammation

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CIRCADIAN RHYTHM; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; SMOKING; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BODY MASS INDEX; C-REACTIVE PROTEIN; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RESIDENCE CHARACTERISTICS; SEX FACTORS;

EID: 0042332075     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200309000-00009     Document Type: Article

References (50)

1. Prescott-Clarke P, Primatesta P. Health Survey for England 1996. London: HMSO; 1998.
2. Hubert H, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977.
3. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277:642-645.
4. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: 'the study of men born before 1913'. Arch Intern Med 1999; 159:1886-1890.
5. Meade TW, Brozovic M, Chakrabarti R, Haines AP, Imenson JD, Mellows S, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart study. Lancet 1986; 2:533-537.
6. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 18:956-963.
7. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14:54-59.
8. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279:1477-1482.
9. Zito F, Drummond F, Bujac SR, Esnouf MP, Morrissey JH, Humphries SE, et al. Epidemiological and genetic associations of activated factor XII concentrations with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation 2000; 102: 2058-2062.
10. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haemtol 1994; 88:601-607.
11. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, et al. The PLAT study: haemostatic function in relation to atherothrombotic ischaemic events in vascular disease patients. Arterioscler Thromb 1992; 12:1063-1070.
12. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332:635-641.
13. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90:61-68.
14. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentrations of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction in apparently healthy young men. Circulation 1994; 90:2236-2240.
15. MacCallum PK, Cooper JA, Howarth DJ, Meade TW, Miller GJ. Sex differences in the determinants of fibrinolytic activity. Thromb Haemost 1998; 79:587-590.
16. Meade TW, Ruddock V, Stirling Y. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart study. Lancet 1993; 342:1076-1079.
17. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94:2057-2063.
18. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor-1 in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9.
19. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93:1271-1276.
20. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
21. Lowe GD, Haverkate F, Thompson SG, Turner RM, Bertina RM, Turpie AG, et al. Prediction of deep vein thrombosis after elective hip replacement surgery by preoperative clinical and haemostatic variables: the ECAT DVT Study. European Concerted Action on Thrombosis. Thromb Haemost 1999; 81:879-886.
22. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation 2001; 103:2323-2327.
23. Lee AJ, Smith WC, Lowe GD, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health study. J Clin Epidemiol 1990; 43:913-919.
24. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997; 97:785-797.
25. Krobot K, Hense HW, Cremer P, Eberle E, Keil U. Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age and sex. Arterioscler Thromb 1992; 12:780-788.
26. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, et al. Associations of fibrinogen, factor VII, and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - The PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80:749-756.
27. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and the risk of cardiovascular disease. The Framingham study. JAMA 1987; 258:1183-1186.
28. Eliasson M, Evrin P, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA study. J Clin Epidemiol 1994; 47:513-524.
29. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39:1044-1048.
30. Sundell IB, Nilsson TK, Ranby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex blood pressure, and body build measurements: a cross-sectional study in Norsjo, Sweden. J Clin Epidemiol 1989; 42:719-723.
31. MacCallum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ. Haemostatic and lipid determinants of prothrombin fragment F1.2 and D-dimer in plasma. Thromb Haemost 2000; 83:421-426.
32. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17:237-246.
33. Miller GJ, Stirling Y, Esnouf MP, Heinrich J, van de Loo J, Kienast J, et al. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994; 71:38-48.
34. World Health Organisation Expert Committee. Physical status: the use and interpretation of anthropometry, WHO Technical Report Series No. 854. Geneva: World Health Organisation; 1995.
35. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumour necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
36. Kopelman PG. Hormones and obesity. Best Pract Res Clin Endocrinol Metab 1994; 8:549-575.
37. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thromboembolism. N Engl J Med 2001; 344:1527-1535.
38. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost 2000; 83:530-535.
39. Medical Research Council's General Practice Research Framework. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ 1996; 312:473-478.
40. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100:717-722.
41. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, sex and risk factors for atheroscrerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70:380-385.
42. Kohler HP, Carter AM, Stickland MH, Grant PJ. Levels of activated FXII in survivors of myocardial infarction - association with circulating risk factors and extent of coronary artery disease. Thromb Haemost 1998; 79:14-18.
43. De Pergola G, De Mitrio V, Giorgino F, Sciaraffia M, Minenna A, Di Bari L, et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 1997; 21:527-535.
44. Rugman FP, Jenkins JA, Duguid JK, Maggs PB, Hay CR. Prothrombin fragment F1 + 2: correlations with cardiovascular risk factors. Blood Coagul Fibrinolysis 1994; 5:335-340.
45. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the haemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13:1865-1873.
46. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor-1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46:860-867.
47. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Wu KK. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70:762-767.
48. Lowe GD, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample-associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999; 81:918-924.
49. Cushman M, Lemaitre RN, Kuller LH, Psaty BM, Macy EM, Sharrett AR, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999; 19:493-498.
50. Lee AJ, Fowkes FGR, Lowe GDO, Rumrey A. Determinants of fibrin D-dimer in the Edinburgh artery study. Arterioscler Thromb 1995; 15:1094-1097.